Novo Nordisk As Stock Buy Hold or Sell Recommendation
| NVO Stock | USD 85.34 1.31 1.56% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Novo Nordisk AS is 'Cautious Hold'. The recommendation algorithm takes into account all of Novo Nordisk's available fundamental, technical, and predictive indicators you will find on this site.
Check out Novo Nordisk Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Novo and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Novo Nordisk AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Novo |
Execute Novo Nordisk Buy or Sell Advice
The Novo recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Novo Nordisk AS. Macroaxis does not own or have any residual interests in Novo Nordisk AS or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Novo Nordisk's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Novo Nordisk Trading Alerts and Improvement Suggestions
| Novo Nordisk AS generated a negative expected return over the last 90 days | |
| Novo Nordisk AS has high historical volatility and very poor performance | |
| Novo Nordisk AS has 27.01 B in debt with debt to equity (D/E) ratio of 0.34, which is OK given its current industry classification. Novo Nordisk AS has a current ratio of 0.9, suggesting that it has not enough short term capital to pay financial commitments when the payables are due. Note however, debt could still be an excellent tool for Novo to invest in growth at high rates of return. | |
| Novo Nordisk AS has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gizmodo.com: Meet Super Ozempic Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial |
Novo Nordisk Returns Distribution Density
The distribution of Novo Nordisk's historical returns is an attempt to chart the uncertainty of Novo Nordisk's future price movements. The chart of the probability distribution of Novo Nordisk daily returns describes the distribution of returns around its average expected value. We use Novo Nordisk AS price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Novo Nordisk returns is essential to provide solid investment advice for Novo Nordisk.
| Mean Return | -0.43 | Value At Risk | -4.07 | Potential Upside | 2.83 | Standard Deviation | 3.09 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Novo Nordisk historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Novo Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Novo Nordisk, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Novo Nordisk AS back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Capital Research & Mgmt Co - Division 3 | 2024-09-30 | 7 M | Polen Capital | 2024-09-30 | 6.9 M | Everett Harris & Co | 2024-09-30 | 6.4 M | State Street Corp | 2024-09-30 | 6.2 M | State Farm Mutual Automobile Ins Co | 2024-09-30 | 6.1 M | Royal Bank Of Canada | 2024-09-30 | 6 M | Blackrock Inc | 2024-09-30 | 5.5 M | Jpmorgan Chase & Co | 2024-09-30 | 5.4 M | Goldman Sachs Group Inc | 2024-09-30 | 4.5 M | Jennison Associates Llc | 2024-09-30 | 20.2 M | Fmr Inc | 2024-09-30 | 17.9 M |
Novo Nordisk Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (895M) | (1.1B) | (4.8B) | (7.4B) | (6.7B) | (6.3B) | |
| Change In Cash | (3.2B) | (1.5B) | 1.9B | 1.7B | 1.6B | 1.6B | |
| Free Cash Flow | 29.9B | 47.6B | 64.1B | 70.0B | 80.5B | 84.5B | |
| Depreciation | 5.8B | 6.0B | 7.4B | 9.4B | 10.8B | 11.4B | |
| Other Non Cash Items | (3.4B) | (2.5B) | 6.3B | 4.9B | 4.4B | 4.6B | |
| Capital Expenditures | 22.1B | 7.4B | 14.8B | 38.9B | 44.7B | 47.0B | |
| Net Income | 42.1B | 47.8B | 55.5B | 83.7B | 96.2B | 101.0B | |
| End Period Cash Flow | 12.2B | 10.7B | 12.7B | 14.4B | 16.6B | 8.9B | |
| Dividends Paid | 20.1B | 21.5B | 25.3B | (31.8B) | (36.5B) | (34.7B) | |
| Investments | (22.4B) | (5.9B) | (24.9B) | (43.9B) | (39.5B) | (37.5B) | |
| Change To Netincome | 6.8B | 8.9B | 10.6B | 22.1B | 25.5B | 26.7B | |
| Net Borrowings | (741M) | 4.7B | 15.5B | (2.4B) | (2.8B) | (2.6B) |
Novo Nordisk Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Novo Nordisk or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Novo Nordisk's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Novo stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.45 | |
β | Beta against Dow Jones | 0.01 | |
σ | Overall volatility | 3.24 | |
Ir | Information ratio | -0.17 |
Novo Nordisk Volatility Alert
Novo Nordisk AS exhibits very low volatility with skewness of -2.43 and kurtosis of 15.46. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Novo Nordisk's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Novo Nordisk's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Novo Nordisk Fundamentals Vs Peers
Comparing Novo Nordisk's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Novo Nordisk's direct or indirect competition across all of the common fundamentals between Novo Nordisk and the related equities. This way, we can detect undervalued stocks with similar characteristics as Novo Nordisk or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Novo Nordisk's fundamental indicators could also be used in its relative valuation, which is a method of valuing Novo Nordisk by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Novo Nordisk to competition |
| Fundamentals | Novo Nordisk | Peer Average |
| Return On Equity | 0.89 | -0.31 |
| Return On Asset | 0.21 | -0.14 |
| Profit Margin | 0.35 % | (1.27) % |
| Operating Margin | 0.47 % | (5.51) % |
| Current Valuation | 377.04 B | 16.62 B |
| Shares Outstanding | 3.36 B | 571.82 M |
| Shares Owned By Institutions | 10.10 % | 39.21 % |
| Number Of Shares Shorted | 8.27 M | 4.71 M |
| Price To Earning | 37.42 X | 28.72 X |
| Price To Book | 22.12 X | 9.51 X |
| Price To Sales | 1.40 X | 11.42 X |
| Revenue | 232.26 B | 9.43 B |
| Gross Profit | 229.07 B | 27.38 B |
| EBITDA | 113.33 B | 3.9 B |
| Net Income | 83.68 B | 570.98 M |
| Cash And Equivalents | 37.47 B | 2.7 B |
| Cash Per Share | 16.57 X | 5.01 X |
| Total Debt | 27.01 B | 5.32 B |
| Debt To Equity | 0.34 % | 48.70 % |
| Current Ratio | 0.92 X | 2.16 X |
| Book Value Per Share | 27.07 X | 1.93 K |
| Cash Flow From Operations | 108.91 B | 971.22 M |
| Short Ratio | 0.85 X | 4.00 X |
| Earnings Per Share | 2.97 X | 3.12 X |
| Price To Earnings To Growth | 1.40 X | 4.89 X |
| Target Price | 111.81 | |
| Number Of Employees | 71.88 K | 18.84 K |
| Beta | 0.17 | -0.15 |
| Market Capitalization | 379.55 B | 19.03 B |
| Total Asset | 314.49 B | 29.47 B |
| Retained Earnings | 104.84 B | 9.33 B |
| Working Capital | (30.01 B) | 1.48 B |
| Current Asset | 8.03 B | 9.34 B |
Novo Nordisk Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Novo . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 159156.0 | |||
| Daily Balance Of Power | 0.5178 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 85.21 | |||
| Day Typical Price | 85.25 | |||
| Price Action Indicator | 0.79 | |||
| Period Momentum Indicator | 1.31 |
About Novo Nordisk Buy or Sell Advice
When is the right time to buy or sell Novo Nordisk AS? Buying financial instruments such as Novo Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Novo Nordisk in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run High Yield ETFs Thematic Idea Now
High Yield ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The High Yield ETFs theme has 105 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize High Yield ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Novo Nordisk Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.224 | Dividend Share 9.9 | Earnings Share 2.97 | Revenue Per Share | Quarterly Revenue Growth 0.214 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.